Buscar
Mostrando ítems 1-10 de 72
Implication of von Willebrand factor as a regulator of tumor cell metastasis: potential perioperative use of desmopressin and novel peptide analogs
(Karger, 2013-05)
Letter to the Editor
Use of desmopressin in children with inherited platelet dysfunctions undergoing adenotonsillar procedures
(2012)
INTRODUCTION AND GOALS:
Adenotonsillar surgery represents a major haemostatic challenge in paediatric patients with mild inherited platelet dysfunction. While there are recommendations for perioperative haemostatic ...
Natural rubber latex: Development and in vitro characterization of a future transdermal patch for enuresis treatment
(Taylor & Francis As, 2017-01-01)
Enuresis affects up to 20% of children of 5 years old, enuretic children present arginine vasopressin secretion deficiency, compared to normal children. To keep the level of antidiuretic hormone in the body, the aim of ...
Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history
(Pergamon-Elsevier Science Ltd, 2007-12)
Antiproliferative effects of oxytocin and desmopressin on canine mammary cáncer cells
(Frontiers Media S.A., 2016-12)
Neoplasms of the mammary gland represent the most frequent tumor type in the femaledog, and according to the histologic criteria, approximately 50% of them are malignant.In the most aggressive cases of mammary cancer, ...
In vitro and in vivo evaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment
(Future Medicine, 2018-11)
Aim: To develop and characterize the antitumor activity of poly(D,L-lactic-co-glycolic acid) nanoparticles loaded with hemostatic and anticancer drug desmopressin (dDAVP). Materials & methods: After full physicochemical ...
The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
(Spandidos Publ Ltd, 2015-06)
Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity. It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on tumour cells and microvasculature. The ...
Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice
(Int Inst Anticancer Research, 2014-07)
Background/Aim: Desmopressin (dDAVP) is a synthetic peptide analog of vasopressin with antidiuretic and hemostatic properties. Recent experimental evidence suggested that dDAVP can inhibit metastasis formation by agonist ...
Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history
(Schattauer Gmbh-Verlag Medizin Naturwissenschaften, 2010)
El cateterismo bilateral y simultáneo de los senos petrosos inferiores en el diagnóstico diferencial del síndrome de Cushing
(Sociedad Médica de Santiago, 2007)